Supernus Pharmaceuticals Inc.
This article was originally published in Start Up
In the early part of this decade, Shire Laboratories was the engine that drove much of Shire PLC's success. The drug delivery unit, which specialized in oral formulations, played a key role in developing many of Shire's top products. Those technologies, as well as existing partnerships, now reside at Supernus Pharmaceuticals, which intends to turn Shire's former drug delivery business into a fully integrated, CNS-focused specialty pharmaceuticals firm.
You may also be interested in...
The IPO drumbeat for drug companies is slow but steady, with valuations looking a bit stronger than 2011. But insider participation, haircuts and dilution are still the order of the day.
Continuing the trend from 2010, biopharma initial public offerings in 2011 are running into stubborn resistance from public investors, a frustrating development as markets otherwise soar to pre-recession levels. More often than not, drug companies are squeezing through the IPO window, which reopened in late 2009, by selling more shares at lower prices. The discounts mean companies raise less cash, and they strain beleaguered venture investors who must hold shares longer to reach an attractive exit price.
A preview of the emerging health care companies profiled in the current issue of Start-Up. This month's profile group: The Good News for Drug Delivery, features profiles of Aequus Biopharma, Macroflux, PharmaKodex, and Supernus. Plus these Start-Ups Across Health Care: Arterial Remodeling Technologies, LifeSync, Marinus Pharmaceuticals, and Tibion.